Plausible therapeutic approaches for inhibiting the excessive BMP signaling in FOP include ALK2 inhibitory RNA technology, anti-ALK2 monoclonal antibodies, and ALK2 small molecule inhibitors [10], [11]. This evidence concerns the gene ACVR1 and fibrodysplasia ossificans progressiva.